Free Trial
NASDAQ:PRAX

Praxis Precision Medicines Q1 2025 Earnings Results & Report

Praxis Precision Medicines logo
$346.21 +8.62 (+2.55%)
Closing price 04:00 PM Eastern
Extended Trading
$346.17 -0.04 (-0.01%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Praxis Precision Medicines missed analyst earnings expectations in its Q1 2025 results, released May 2, 2025. The company reported EPS of -$3.29 versus the -$3.20 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

Praxis Precision Medicines EPS Results

Actual EPS
-$3.29
Consensus EPS
-$3.20
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Praxis Precision Medicines Revenue Results

Actual Revenue
N/A
Expected Revenue
$196 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Praxis Precision Medicines Q1 2025 Earnings FAQ

Praxis Precision Medicines (NASDAQ:PRAX) reported earnings of -$3.29 per share for Q1 2025, missing the consensus estimate of -$3.20. The report was announced on Friday, May 2, 2025.

Praxis Precision Medicines Earnings Headlines

Praxis Precision Medicines (NASDAQ:PRAX) Earns Buy Rating from BTIG Research
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Praxis Precision Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Praxis Precision Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Praxis Precision Medicines and other key companies, straight to your email.

About Praxis Precision Medicines

Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity.

Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Praxis is headquartered in Boston, Massachusetts, and is led by co-founder and Chief Executive Officer Marcio Souza.

View Praxis Precision Medicines Profile